ROL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy now. ROL is in a broader uptrend (bullish moving-average stack), is trading near a defined support zone (~62.18/61.73), and sentiment from options positioning and recent Wall Street upgrades leans bullish with clear upside to the prevailing $70–$72 targets. Near-term momentum is soft (bearish MACD, RSI ~42) and insider selling is a real negative, but for an impatient buyer the current pullback into support offers a reasonable entry ahead of the Feb-11 earnings catalyst.
Trend/structure: Bullish longer-term structure with SMA_5 > SMA_20 > SMA_200 (trend still up). Near-term momentum has weakened: MACD histogram is negative (-0.00544) and expanding lower, and RSI_6 at 42.39 shows fading momentum (not oversold, but leaning weak). Key levels: Pivot 62.923. Price 62.41 is below pivot (near-term bearish bias) but sitting just above S1 62.182; next support S2 61.725. A rebound reclaiming 62.923 improves the setup; a push through 63.663 (R1) would confirm short-term strength. Quant pattern read-through: Similar-pattern stats skew slightly negative (-1.37% next day, -1.81% next week), so this is more of a ‘buy near support’ entry than a momentum chase.
Intellectia Proprietary Trading Signals
Earnings catalyst ahead: QDEC 2025 earnings on 2026-02-11 (after hours) can reset expectations if organic growth/margins surprise positively.
Wall Street tone improved: multiple upgrades/initiations to bullish ratings with $70–$72 targets.
Fundamentals trending well: strong YoY growth in revenue, net income, and EPS (latest reported quarter: 2025/Q3).
Shareholder return: declared quarterly dividend $0.1825 (news 2026-01-23).
Insider selling: insiders are net sellers and selling increased sharply (+2454.19% over the last month), which can cap near-term upside.
Near-term technical momentum is weak: negative/expanding MACD and RSI in the low-40s.
Pre-earnings risk: UBS highlighted risk-reward into results as ‘balanced,’ implying potential for a muted reaction if guidance is merely in-line.
Short-term pattern odds slightly bearish over the next day/week.
Latest quarter provided: 2025/Q3. Revenue grew to $1.026B (+11.99% YoY), net income rose to $163.5M (+19.44% YoY), and EPS increased to $0.34 (+21.43% YoY). Gross margin improved to 51.3% (+0.71% YoY). Overall, growth and profitability trends are improving, supporting the bull case into the next reporting season (QDEC 2025 earnings on 2026-02-11).
Recent trend: analyst sentiment has strengthened materially. Bernstein initiated Outperform ($70). Barclays upgraded to Overweight ($72). Morgan Stanley upgraded to Overweight ($72). UBS raised PT to $65 but stays Neutral. Wall Street pros: durable demand/structural tailwinds, ‘best-in-class’ operator narrative, potential for continued estimates to move up. Wall Street cons: expectations may already be well-known into earnings (UBS ‘balanced’ setup), limiting upside surprise unless results/guidance beat clearly. Influential/political trading: No recent congress trading data available; no politician/influential figure trades were provided.
